Key result
This review discusses cytotoxic anti-neoplastic and targeted drugs, radiation-induced cardiovascular diseases, their mechanisms, and strategies for treatment, monitoring, and detection.
This review highlights the growing importance of cardio-oncology in managing and mitigating cardiovascular toxicities associated with modern cancer therapies.
Emphasizes cardio-oncology integration in cancer care; leaves open optimal monitoring protocols pending prospective trials.
Cancers and cardiovascular diseases are the leading causes of death among humans. Given the increasing armamentarium of cancer treatments with a potential for cardiovascular toxicity, cytotoxic and molecularly targeted drugs, radiation-associated cardiovascular toxicity is an increasing problem both for both the oncologist and cardiologist, which suggests a need for cardio-oncology (or onco-cardiology) to minimize the knowledge gap between these fields and to determine the best strategies to help recognize, detect, treat, prevent, and predict these adverse cardiovascular events. In this review, we will briefly discuss the cytotoxic anti-neoplastic and targeted drugs and various radiation-induced cardiovascular diseases with their potential mechanisms, and strategies for treatment, monitoring, and detection.
No takes yet. Share an insight, caveat, or question.
Shaozhong Wei (2014) conducted a review in Chemoradiotherapy-Associated Cardiovascular Toxicity. Chemoradiotherapy was evaluated. This review discusses cytotoxic anti-neoplastic and targeted drugs, radiation-induced cardiovascular diseases, their mechanisms, and strategies for treatment, monitoring, and detection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: